Outcome of Board Meeting held on January 30, 2026.

Bharat Parenterals' board approved its Q3FY26 results on January 30, 2026, with statutory auditors issuing an unmodified review opinion on both standalone and consolidated numbers. Standalone revenue from operations stood at ₹41.41 crore, roughly flat sequentially but down 38.5% YoY from ₹67.34 crore, which the company attributes to timing-related deferment of institutional purchase orders under existing rate contracts. Standalone PAT fell to ₹1.95 crore (vs ₹6.51 crore in Q3FY25), though EBITDA margin recovered sequentially to 8.4% from 5.6% on cost discipline. On a consolidated basis, the company posted a net loss of ₹9.63 crore for the quarter and ₹19.15 crore for 9M FY26, driven by continued investment and losses at subsidiaries Innoxel Lifesciences, Varenyam Biolifesciences, and Varenyam Healthcare. Management disclosed an order book of ₹303 crore for the first time, expects standalone Q4FY26 revenue of ₹50–55 crore, and conceded that full-year FY26 guidance will be missed due to institutional timing shifts, with a meaningful spill-over expected in H1FY27.